Drugmaker Merck reports quarterly results Thursday morning as fears grow over the expiration of the patent on its top-selling ...

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

The deal is expected to close in the second quarter of 2025. Jiangsu Hengrui Pharma has given Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 worldwide, except in ...

Last year Merck agreed a similar licensing deal, also worth $2 billion, for Chinese biotech Hansoh Pharma’s experimental oral obesity drug, while yesterday Denmark’s Novo Nordisk (NVO ...

Merck on Tuesday said it will make an upfront payment of $200 million to Hengrui Pharma to license HRS-5346, which is currently in a Phase 2 study in China for the reduction of lipoprotein(a), or ...

Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 worldwide, excluding the Greater China region. Hengrui Pharma will ...